search
Back to results

Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease

Primary Purpose

Symptomatic Cervical Degenerative Disc Disease (DDD) From C3-C7

Status
Unknown status
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Freedom Cervical Disc
Sponsored by
AxioMed Spine Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Symptomatic Cervical Degenerative Disc Disease (DDD) From C3-C7 focused on measuring Cervical DDD, DDD, degenerative disc disease, C3-C7

Eligibility Criteria

21 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Skeletally mature males or females, aged 21 to 65 years old, inclusive.
  • Single, or adjacent, 2-level degenerative disc disease at C3-C7, inclusive.
  • Subject is a surgical candidate for an anterior approach to the cervical spine.
  • Minimum of 6 weeks of unsuccessful conservative treatment.
  • Subject with at least moderate preoperative pain and functional impairment
  • Subject is mentally and physically able to comply with protocol, postoperative compliance instructions, and follow-up schedule through 2-years.
  • Subject must understand and sign the written Informed Consent form.

Exclusion Criteria:

  • Subject with axial neck pain only who does not demonstrate concurrent arm pain or progressive neurological deterioration (specifically numbness or muscle weakness in the arm).
  • An active infection at the operative site or active systemic infection at the time of surgery.
  • Known or suspected allergy to titanium, polyurethane, cobalt, chromium, molybdenum or silicone.
  • Previous spinal fusion at the involved, or adjacent, cervical level(s).
  • Congenital or acquired structural defect at the operative levels (s) or their immediately adjacent level(s).
  • Significant osteoporosis in the cervical spine.
  • The investigator should assess if the subject has any of the following conditions at the index or adjacent level(s) which excludes the subject from study participation:
  • Cervical facet degeneration of the involved C3-C7 levels.
  • Previous trauma to, or fusion in, the C3-C7 levels.
  • Cervical instability at the index level(s) on neutral lateral or flexion/extension x-rays.
  • Radiographic findings of a fused or total collapsed disc.
  • Significant global cervical kyphosis (≥15º on Cobb angle measurement) or significant reversal of lordosis.
  • Female of childbearing potential, pregnant, breast feeding, or interested in becoming pregnant in the next two years

Sites / Locations

  • Universitatsklinikum Bonn
  • Stadtisches Klinikum Gorlitz
  • Stadtisches Klinikum Karlsruhe
  • Klinik St. Anna
  • Spine Center Rischke

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Freedom Cervical Disc

Arm Description

Outcomes

Primary Outcome Measures

Safety of FCD
Monitor the safety (operative and post-operative adverse events through 6-months) of the FCD.
Performance of FCD
Monitor the performance (radiographic evaluation of segmental non-fusion and device function) of the FCD through 6-months post-operative period.

Secondary Outcome Measures

Incidence of AEs
Examine the incidence of adverse events including device revision, removal or supplemental fixation through the 2-years post-operative period.
Neck/Arm Pain
Examine changes in neck and arm pain throughout the 2-years post-operative period.
Neurological function
Examine changes in subject neurological function throughout the 2-years post-operative period.
Subject Function
Examine changes in subject function throughout the 2-years post-operative period.
Radiographic Measurements
Examine changes in radiographic measurements of the target, adjacent and cervical segment levels from discharge through the 2-years.
Examine AEs
Examine all adverse events throughout the 2-years post-operative period

Full Information

First Posted
January 4, 2013
Last Updated
July 28, 2016
Sponsor
AxioMed Spine Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT01763619
Brief Title
Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease
Official Title
Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Unknown status
Study Start Date
February 2013 (undefined)
Primary Completion Date
July 2017 (Anticipated)
Study Completion Date
July 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AxioMed Spine Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will collect clinical and radiographic data on the Freedom Cervical Disc to monitor the device's safety and performance as part of a post-market evaluation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Symptomatic Cervical Degenerative Disc Disease (DDD) From C3-C7
Keywords
Cervical DDD, DDD, degenerative disc disease, C3-C7

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Freedom Cervical Disc
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Freedom Cervical Disc
Primary Outcome Measure Information:
Title
Safety of FCD
Description
Monitor the safety (operative and post-operative adverse events through 6-months) of the FCD.
Time Frame
6 months
Title
Performance of FCD
Description
Monitor the performance (radiographic evaluation of segmental non-fusion and device function) of the FCD through 6-months post-operative period.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Incidence of AEs
Description
Examine the incidence of adverse events including device revision, removal or supplemental fixation through the 2-years post-operative period.
Time Frame
2 year
Title
Neck/Arm Pain
Description
Examine changes in neck and arm pain throughout the 2-years post-operative period.
Time Frame
2 years
Title
Neurological function
Description
Examine changes in subject neurological function throughout the 2-years post-operative period.
Time Frame
2 years
Title
Subject Function
Description
Examine changes in subject function throughout the 2-years post-operative period.
Time Frame
2 years
Title
Radiographic Measurements
Description
Examine changes in radiographic measurements of the target, adjacent and cervical segment levels from discharge through the 2-years.
Time Frame
2 years
Title
Examine AEs
Description
Examine all adverse events throughout the 2-years post-operative period
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Skeletally mature males or females, aged 21 to 65 years old, inclusive. Single, or adjacent, 2-level degenerative disc disease at C3-C7, inclusive. Subject is a surgical candidate for an anterior approach to the cervical spine. Minimum of 6 weeks of unsuccessful conservative treatment. Subject with at least moderate preoperative pain and functional impairment Subject is mentally and physically able to comply with protocol, postoperative compliance instructions, and follow-up schedule through 2-years. Subject must understand and sign the written Informed Consent form. Exclusion Criteria: Subject with axial neck pain only who does not demonstrate concurrent arm pain or progressive neurological deterioration (specifically numbness or muscle weakness in the arm). An active infection at the operative site or active systemic infection at the time of surgery. Known or suspected allergy to titanium, polyurethane, cobalt, chromium, molybdenum or silicone. Previous spinal fusion at the involved, or adjacent, cervical level(s). Congenital or acquired structural defect at the operative levels (s) or their immediately adjacent level(s). Significant osteoporosis in the cervical spine. The investigator should assess if the subject has any of the following conditions at the index or adjacent level(s) which excludes the subject from study participation: Cervical facet degeneration of the involved C3-C7 levels. Previous trauma to, or fusion in, the C3-C7 levels. Cervical instability at the index level(s) on neutral lateral or flexion/extension x-rays. Radiographic findings of a fused or total collapsed disc. Significant global cervical kyphosis (≥15º on Cobb angle measurement) or significant reversal of lordosis. Female of childbearing potential, pregnant, breast feeding, or interested in becoming pregnant in the next two years
Facility Information:
Facility Name
Universitatsklinikum Bonn
City
Bonn
ZIP/Postal Code
53105
Country
Germany
Facility Name
Stadtisches Klinikum Gorlitz
City
Gorlitz
ZIP/Postal Code
02828
Country
Germany
Facility Name
Stadtisches Klinikum Karlsruhe
City
Karlsruhe
ZIP/Postal Code
76133
Country
Germany
Facility Name
Klinik St. Anna
City
Luzern
ZIP/Postal Code
CH-6006
Country
Switzerland
Facility Name
Spine Center Rischke
City
Zurich
ZIP/Postal Code
CH 8001
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease

We'll reach out to this number within 24 hrs